Skip to main content
. Author manuscript; available in PMC: 2013 Mar 1.
Published in final edited form as: Alcohol Clin Exp Res. 2011 Sep 26;36(3):406–416. doi: 10.1111/j.1530-0277.2011.01649.x

Figure 3.

Figure 3

Additional Subgroup Analyses

Means are LSMEANS from unadjusted mixed models on nontransformed outcome variables (Weeks 3–11). Error bars are 95% confidence intervals.

P-values for interactions are from mixed models on appropriately transformed outcome variables adjusted for gender, reducer status, center, and baseline value of the outcome.

aThe variable “side effects” was determined by the presence of at least 1 of the following adverse events: dizziness, dry mouth, dyspepsia, increased appetite, sedation, and somnolence.

bThe cut-off, 12,600mg, is 50% of 25,200mg, the total possible amount of medication that could be taken during the maintenance period (weeks 3–11).

cA score of >5 is indicative of poor sleep quality.